Tech Company Financing Transactions

Avilar Therapeutics Funding Round

Avilar Therapeutics closed a Seed funding round on 2/16/2023. Investors included Astellas Venture Capital, Medical Excellence Capital and Sanofi Ventures.

Transaction Overview

Company Name
Avilar Therapeutics
Announced On
2/16/2023
Transaction Type
Venture Equity
Amount
Unknown
Round
Seed
Investors

Astellas Venture Capital (Lead Investor)

Medical Excellence Capital (Lead Investor)

Sanofi Ventures (Lead Investor)

RA Capital (Josh Resnick)

Proceeds Purpose
The company intends to use the funds to advance multiple degrader pipeline programs for the treatment of autoimmune, neurological, and other diseases driven by pathogenic extracellular proteins, to expand the platform of proprietary technologies, all custom-built and tailored to designing and building extracellular protein degraders.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
200 Berkeley St. 18th Floor
Boston, MA 02116
USA
Phone
Undisclosed
Website
www.avilar-tx.com
Email Address
[email protected]
Overview
Avilar is pioneering the next frontier in protein degradation by targeting extracellular proteins. Targeted protein degradation has emerged as a powerful new drug modality with applications in a broad range of diseases.
Profile
Avilar Therapeutics LinkedIn Company Profile
Social Media
Avilar Therapeutics Company Twitter Account
Company News
Avilar Therapeutics News
Facebook
Avilar Therapeutics on Facebook
YouTube
Avilar Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Daniel Grau
  Daniel Grau LinkedIn Profile  Daniel Grau Twitter Account  Daniel Grau News  Daniel Grau on Facebook
Chief Scientific Officer
Effie Tozzo
  Effie Tozzo LinkedIn Profile  Effie Tozzo Twitter Account  Effie Tozzo News  Effie Tozzo on Facebook
Vice President
Kevin Lumb
  Kevin Lumb LinkedIn Profile  Kevin Lumb Twitter Account  Kevin Lumb News  Kevin Lumb on Facebook
Vice President
Jason Wiles
  Jason Wiles LinkedIn Profile  Jason Wiles Twitter Account  Jason Wiles News  Jason Wiles on Facebook
VP - Bus. Development
Phil Graham
  Phil Graham LinkedIn Profile  Phil Graham Twitter Account  Phil Graham News  Phil Graham on Facebook

 

 

Browse more venture capital transactions:

Prev: 2/16/2023: AdalFi venture capital transaction
Next: 2/16/2023: IncludeHealth venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to report on every notable VC transaction. VC transactions reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.